

INFORMAZIONI PERSONALI

Pennacchioli Elisabetta

📍 via Verrocchio 30, 20129 Milano (Italia)
☎ (+39) 3395936024 📠 (+39) 02 57489485
✉ elisabetta.pennacchioli@ieo.it

POSIZIONE RICOPERTA

SURGICAL ONCOLOGIST

ESPERIENZA
PROFESSIONALE

01/05/2018–alla data attuale

Director Melanoma, Soft Tissue Sarcoma and Rare Tumors Program

European Institute of Oncology, Milan (Italia)

National and International co-operation- **EORTC**- **CTOS**- Retroperitoneal soft tissue sarcomas. **TARPSWG** (Trans-Atlantic Retroperitoneal Sarcoma working Group)- **RE**troperitoneal **SA**rcoma **REG**istry (RESAR): (TARPSWG Prospective Registry)- Retrospective database of pelvic, abdominal and retroperitoneal **schwannomas**- **Chordoma** Foundation- **ISG**- **Rete Nazionale Tumori Rari**- **Desmoid Tumor Research Foundation**

- Familial and Multiple Melanoma Genetics - regional referral center for rare tumours

Projects:

- *Primary cell culture from angiosarcoma and TET: validation as representative preclinical disease model usefull to test in vitro and in vivo activity of new therapies*- *Characterization of pathogenetic role of hormonal pathway (ER) in phylodes tumors*- *M-Skip Project (international collaborative group to study the MC1R gene in childhood within the SKin cancer and Phenotypic characteristics)*- *Advanced diagnostic and applied research center aimed at:**primary prevention of melanoma and non-melanoma skin cancer**early diagnosis of melanoma and non-melanoma skin cancer (High resolution digital dermoscopy; Laser confocal microscopy)*• *Isolated limb perfusion with trabectedin for the treatment of local soft tissue sarcoma: dose escalation driven by pharmacokinetics (M. Negri)*• *Advancing the aetiology of soft tissue sarcoma: risk factors in an epidemiological interdisciplinary study (M. Negri)*• *Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma (STRASS). EORTC*• *Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial (EORTC)*

12/06/2015–30/04/2018

Melanoma and Soft Tissue Sarcoma Surgical Division Director

European Institute of Oncology
via Ripamonti 435, 20141 Milan Milan (Italia)www.ieo.it

In charge for the **Surgical activity** inside the **Multidisciplinary Team** dedicated to Soft Tissue Sarcoma.

Clinical research:

- *Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STs 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial (ISG).*
- *Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma (STRASS)*
- β
on protein structure and gene expression
- *Advancing the aetiology of soft tissue sarcoma": risk factors in an epidemiological interdisciplinary study (Mario Negri Institute and Istituto Nazionale Tumori, Milan)*
- *Trabectedina (ET743) in pazienti affetti da liposarcoma mixoide/rotondocellulare con malattia metastatica o localmente avanzata pretrattati con chemioterapia con antraciclina e ifosfamide in associazione o in sequenza.*
- *Sperimentazione clinica di fase 2 per valutare l'attività di crizotinib (PF-02341066) in Pazienti portatori di diverse tipologie di tumori maligni indotti da alterazioni di ALK e/o di MET, in stadio avanzato di malattia ("CREATE").*
- *Studio di fase II, randomizzato ma non comparativo, per valutare l'attività di trabectedina oppure gemcitabina + docetaxel in pazienti affette da leiomiomasarcoma dell'utero in recidiva locale o a distanza e pretrattate con chemioterapia convenzionale*
- *Studio a bracci multipli, multicentrico , di fase Ib di valutazione della dose di imatinib in associazione all'inibitore orale della fosfatidil-inositolo-3 chinasi (PI3-K) BKM120 in pazienti con tumori gastrointestinali stromali (GIST) che abbiano fallito la terapia precedente con imatinib e sunitinib.*
- *Studio di fase II per valutare l'attività e la sicurezza di Everolimus in associazione a Imatinib come terapia di prima linea nei pazienti affetti da tumore stromale gastrointestinale, caratterizzato da mutazione a carico dell'esone 18 del gene PDGFRA (D842V), in fase metastatica e/o avanzata.*
- *TR1US "Trabectedin first line therapy in unfit sarcoma study" - Safety and activity of trabectedin as first line in advanced soft tissue sarcoma (sts) patients unfit to receive standard chemotherapy: a prospective phase ii study with clinical and molecular correlates (tr1us). Italian Sarcoma Group*
- *TRAVELL "A phase II study on trabectedin in advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma - isg-sts-trab-2012". Italian Sarcoma Group.*
- *ATREUS "A phase II study on the activity of trabectedin in pretreated epithelioid or biphasic/sarcomatoid malignant pleural mesothelioma (mpm)". MARIO NEGRI*
- *TOMAS – Combinazione Trabectedina – Olaparib nei STS*
- *adroterapia dei Sarcomi del Retroperitoneo (CNAO)*
- *radiomica nei STS*

02/04/2014–11/06/2015

Soft Tissue Sarcoma Surgical Unit Director

European Institute of Oncology, Milan (Italia)

In charge for the **Surgical activity** inside the **Multidisciplinary Team** dedicated to Soft Tissue Sarcoma.

Clinical research:

A Phase IIb study of topic DAC-0060, a synthetic histone deacetylase inhibitor, plus Tazarotene in patients with cutaneous basal cell carcinoma (BCC). IEO 814/13 F. EudraCT N. 2013-003336-72. SPONSOR: European Institute of Oncology

Locally advanced, non-resectable condrosarcoma. Observational study. 2013. Coordinators: Stefano Ferrari, Sezione di Chemioterapia dei Tumori dell'Apparato Locomotore, Istituto Ortopedico Rizzoli, Bologna. Virginia Ferraresi, Oncologia Medica, Istituto Regina Elena, Roma

Adult Rhabdomyosarcoma. observational study. maggio 2011. Coordinators: Rossella Bertulli, Oncologia Medica, Fondazione IRCCS Istituto Nazionale Tumori Milano. Andrea Ferrari, Oncologia Pediatrica, Fondazione IRCCS Istituto Nazionale Tumori, Milano.

CASE-CONTROL STUDY ON RISK FACTORS OF SOFT TISSUE SARCOMA. STUDY PROTOCOL V.01/2014 - 20/02/2014. Coordinating study centers: Dipartimento di Epidemiologia Istituto di Ricerche Farmacologiche "Mario Negri", Milano. Azienda Ospedaliera C.T.O. Maria Adelaide di Torino, S.C. Traumatologia, Ortopedia e Medicina del Lavoro, Torino.

01/10/2010–01/04/2014

Deputy Director in Melanoma and Sarcoma Unit

European Institute of Oncology, Milan (Italia)

Dedicated surgeon in a Multidisciplinary Team that deals with Melanoma and Soft Tissue Sarcoma

Clinical research:

- *MelaViD: Phase III, randomized, double blind trial on Vitamin D supplementation for resected stage II melanoma patients.*
- *Clinical National Melanoma Registry (CNMR)*
- *Prognostic role of melanoma follow up. A prospective randomised study*
- *A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit*
- *A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects with Previously Untreated Unresectable or Metastatic Melanoma*
- *A Randomized, Open-Label Phase 3 Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.*
- *Phase III, randomized, double blind, placebo-controlled study of vemurafenib (ro5185426) adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence*
- *Oncology Clinical Trial Protocol CMEK162B2301 COLUMBUS – Combined LGX818 Used with MEK162 in BRAF mutant Unresectable Skin cancer*
- *COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBination with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection*
- *An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1-positive unresectable and progressive metastatic cutaneous melanoma*
- *Clinical Protocol CA209067 A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Subjects with Previously Untreated Unresectable or Metastatic Melanoma.*
- *Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group. EORTC protocol 18071*
- *MEK114267, A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma*
- *An open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma RO5185426 EUDRACT NUMBER 2010-023526-21*
- *A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous Melanoma*
- *COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBination with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection.*
- *A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIC) or metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma*
- *Adjuvant Pegylated-Interferon-alpha2b (Sylatron™) for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC*

Melanoma Group

- A Phase IIb study of topic DAC-0060, a synthetic histone deacetylase inhibitor, plus Tazarotene in patients with cutaneous basal cell carcinoma (BCC)

- IEO S597/111 Study first in man, escalation dose, of SAR125844 as single agent, in adult patients with advanced solid tumors.

- IEO S619/211 Localized high-risk soft tissue sarcomas of the extremities and trunk wall in adults: an integrating approach comprising standard vs histotype-tailored neoadjuvant chemotherapy (ISG-STS 10-01)

- IEO S754/612 Genetic and soluble isoform of CTLA-4 polymorphisms as prognostic and predictive factor in melanoma.

- IEO 0068/ Circulating hepatocyte growth factor as prognostic and predictive factor in patients with B-RAF mutant melanoma and in B-RAF inhibitor therapy.

19/06/2001–30/09/2010

Attending Surgeon

National Cancer Institute
via Venezian 1, 20129 Milan (Italia)
www.istitutotumori.mi.it

Attending Surgeon at the Melanoma and Sarcoma Department at the National Cancer Institute of Milan, directed by Dr. Mario Santinami.

Projects:

-CV-MMAIT-4-001 : A phase III randomized Double-Blind Trial of Immunotherapy with a Polyvalent Melanoma Vaccine, Cancer Vax™ Vaccine plus BCG versus Placebo plus BCG as a post-surgical Treatment for Stage IV Melanoma

-EORTC MG Trial 18991: Peg Intron Adjuvant Therapy in stage IIIB Melanoma

-Antigenics Protocol C-100-22 : Open label, non-randomized Phase II study of Heat Shock Protein-Peptide Complex (HSPPC-96) in combination with GM-CSF and IFN- α in subjects with Stage IV resectable malignant melanoma.

-EORTC MG : Phase I-II study on Isolation Limb Antiplastic Perfusion with Fotemustine after Chemosensitization with Dacarbazine in Melanoma of the extremities (Stage II, IIIA and IIIAB).

-WHO Melanoma Program: Data base on Sentinel node survey.

-WHO Melanoma Program : Colecoxib plus GM-CSF as an Adjuvant Therapy in High-Risk Melanoma

01/11/1999–18/06/2000

Attending Surgeon

National Cancer Institute, Milan (Italia)

Consultant in the Department of Loco-Regional Treatments at the National Cancer Institute of Milan, directed by Dr. M. Vaglini, with main interest in Melanoma and Sarcoma.

-Research project: Evaluation of Cytoreductive Surgery (Peritonectomy) and Intra Peritoneal Hyperthermic Perfusion in patients affected by Pseudomyxoma Peritonei and Mesothelioma. A phase II clinical study.

01/09/1998–01/10/1999

Clinical Fellow/Associate physician

Royal's Women Hospital, Melbourne (Australia)

Non-full staff position as Surgeon

Health care: Urology and Urogynecology

01/07/1996–30/06/1998

Attending Surgeon

Ospedale San Raffaele, Milano (Italia)

Consultant for the Department of Urology in the San Raffaele Hospital directed by Prof. Rigatti.

-Paediatric urology: endocrine surgery (adrenal diseases, with interest in adreno-genital syndrome) and urological malformations.

-Urodynamics and urogynecology in pelvic reconstructive surgery.

- 01/06/1995–30/05/1996 **Clinical Fellow/ Associate Physician**
Ospedale San Raffaele, Milano (Italia)
Resident in the Division of Paediatric Surgery, in the Department of General Surgery directed by Prof. V. Di Carlo and keeping as main interest endocrine diseases.
- 20/05/1995–01/07/1998 **Clinical Fellow/ Associate Physician**
Ospedale San Raffaele, Milano (Italia)
Resident in the Department of General Surgery, Hepato-Biliary-Pancreatic Surgery and Emergency Surgery directed by Prof. V. Di Carlo.
- 01/09/1989–01/07/1995 **Clerkship**
Ospedale San Raffaele, Milano (Italia)
Clerkship in Surgery in the department run by Prof. Di Carlo.
Clinical activity and research:
-in the surgical ward: abdominal surgery with particular interest on endocrine diseases (gastro-entero-pancreatic neuroendocrine system, thyroid and parathyroid, adrenal), and in clinical research antibody-guided surgery in cancer patients (I-125 biotinylated monoclonal antibodies and cold avidin)
-in research: Pancreatic Islet Cell Transplantation (Isulae Isolation and Criopreservation, Immunology)
- 01/01/1988–01/06/1989 **Clerkship**
Ospedale San Raffaele, Milano (Italia)
Clerkship in Internal Medicine wards directed by Prof. Pozza.
Interest in metabolic diseases, especially Diabetes Mellitus and experience with kidney and pancreas transplantation.
- 01/01/1987–01/12/1987 **Clerkship**
Ospedale San Raffaele, Milano (Italia)
Clerkship in the Department of Human Physiology of the Università degli Studi in Milan, Prof Cerretelli.
- 01/01/1986–01/12/1986 **Clerkship**
Ospedale Niguarda, Milano (Italia)
Clerkship in Pathology, director Prof. Sfondrini.

ISTRUZIONE E FORMAZIONE

- 01/10/1990–01/07/1995 **Board Certificate in General Surgery (70/70 with honors)**
Università degli Studi di Milano, Milano (Italia)
ISCED 5A (Field of Education: 72)
*discussant a thesis entitled: *Diagnosis and Surgical Treatment of Pancreatic Insulinomas.**
- 01/11/1991 **Italian Medical Licence**
- 01/10/1984–22/10/1990 **Medical Degree (110/110 with honors)**
Università degli Studi di Milano, Milano (Italia)
ISCED 5A (Field of Education: 72)

discussant a thesis entitled: *Diagnosis and Treatment of Neuroendocrine Tumors of the Pancreas*.

COMPETENZE PERSONALI

Lingua madre italiano

Lingue straniere	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
inglese	C1	C1	C1	C1	C1

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato
Quadro Comune Europeo di Riferimento delle Lingue

Competenze comunicative Excellent communication skills, gained during training with the program dedicated to physicians, managed by the Department of Psycho-Oncology at the National Cancer Institute of Milan.

Competenze organizzative e gestionali Leadership (responsabile di un gruppo chirurgico di lavoro, in ambito multidisciplinare)

Competenze professionali

- Member of the Society of Surgical Oncology (SSO)
- Member of Sitilo (Società Italiana di Terapie Integrate loco-regionali in Oncologia)
- Member of Italian Sarcoma Group
- Member of European society of Medical Oncology (ESMO)
- Qualified to practice medicine and surgery in Switzerland

Competenze digitali

Windows
Mac
Microsoft Office
E-mail
Navigazione web

ALLEGATI

- other responsibilities 2015 en.pdf
- biblio 2018.pdf
- List of Book chapters 2018.pdf

other responsibilities 2015 en.pdf

TEACHING RESPONSIBILITIES

- **Teaching Medical Students**

Lectures within the Medical School

Formal case presentations and clinical examinations

Lectures on the anatomy of the abdomen, peritoneum and musculo-skeletal system

Mentorship program for medical students

- **Teaching Surgical Residents**

Lectures in General Surgery

Teaching basic surgical techniques

Teaching in the operatory room

Teaching basic principles of experimental surgical techniques

Organization and teaching in seminars and workshop in Melanoma and Sarcoma

Mentorship program for surgical residents

- **Teaching Nurses and Operatory Room Nurses**

Formal lectures in the School of Nurses in general and oncologic surgery

SURGICAL EXPERIENCE

SURGICAL ONCOLOGY

- *SOFT TISSUE SARCOMA*
 - Wide muscular excision
 - Wide muscular excision en bloc with bone resection
 - Toracotomy and ribs reconstruction
 - Wide excision of the abdominal wall and plastic reconstruction
 - Ileal resection (Gist)
 - Retroperitoneal compartmentectomy en bloc with nephrectomy, colectomy, psoas muscle resection, spleno-pancreatectomy, resection of the diaphragm
 - Isolate limb perfusion with TNF and Melphalan, in CEC.
 - Amputation
 - Disarticulation
 - Breast quadrantectomy
 - Mastectomy
 - Citoriduction + CHIP

- *MELANOMA*
 - Wide excision and sentinel node biopsy
 - Wide excision and plastic reconstruction
 - Axillary lymphadenectomy
 - Superficial and deep inguinal lymphadenectomy
 - Latero-cervical lymphadenectomy (levels I-V)
 - Latero-cervical lymphadenectomy and parotidectomy
 - Electro-Chemo-Therapy
 - **Isolated limb perfusion with Melphalan in CEC.**

GENERAL SURGERY, PEDIATRIC SURGERY, UROLOGY, PEDIATRIC UROLOGY (as Surgeon or Assistant)

- Appendicectomy

- Inguinal herniorraphy
- Kelectomy
- Cutaneous wide excision
- Orchidopexy
- Circumcision
- Extra-mucosal miotomy
- Colostomy
- Duodenopancreatectomy
- Distal Pancreatectomy
- Intermediate Pancreatectomy
- Liver resection
- Necrosectomy in Acute Pancreatitis
- Distal aortic Aneurismectomy
- Splenectomy
- Cholecistectomy
- Total Gatrectomy
- Gastric resection
- Esofagectomy
- Ileal Resection
- Meckel diverticulectomy
- Right hemicolectomy
- Left hemicolectomy
- Rectum resection
- Total Colectomy
- Colostomy
- Uretero-bladder reconstruction
- Reconstruction of pielo-ureteral joint

ADMINISTRATIVE RESPONSIBILITIES

- Director of Sarcoma Surgery Unit at European Institute of Oncology, Milan
- Deputy director in Melanoma and Sarcoma Surgery at European Institute of Oncology, Milan

biblio 2018.pdf 

1. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Oncol.* 2018 Apr 1;29(4):857-871.
2. Giulio Tosti, Anna Daniela Iacobone, Eleonora Petra Preti, Sabina Vaccari, Alessia Barisani, Elisabetta Pennacchioli, Carmen Cantisani. The Role of Photodynamic Therapy in the Treatment of Vulvar Intraepithelial Neoplasia. *Biomedicines.* 2018 Mar; 6(1): 13. Published online 2018 Feb 2
3. De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, Geppetti P, Gandini S. Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. *JAMA Oncol.* 2018 Feb 8;4(2):e172908. doi: 10.1001/jamaoncol.2017.2908. Epub 2018 Feb 8.
4. Erratum to: Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. Trans-Atlantic RPS Working Group. *Ann Surg Oncol.* 2017 Dec;24(Suppl 3):688-689.
5. Gilardi L, Vadrucci M, Pittaro A, Pennacchioli E, Rizzo S. 18F-FDG PET/CT in aggressive angiofibroma of the pelvis. *Rev Esp Med Nucl Imagen Mol.* 2017 Nov - Dec;36(6):403-405. doi: 10.1016/j.rem.2017.03.005. Epub 2017 Apr 22.
6. Caini S, Radice D, Tosti G, Spadola G, Coccorocchio E, Ferrucci PF, Testori A, Pennacchioli E, Fagnoli MC, Palli D, Bazolli B, Botteri E, Gandini S. Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy. *J Eur Acad Dermatol Venereol.* 2016 Sep;30(9):1491-6. doi: 10.1111/jdv.13645. Epub 2016 Mar 18
7. Giulio Tosti, Emilia Coccorocchio, Elisabetta Pennacchioli. Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. *Clin Cosmet Investig Dermatol.* 2013; 6: 245-256. Published online 2013 Oct 17.
8. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. *Eur J Cancer.* 2014 Nov;50(17):3021-8. doi: 10.1016/j.ejca.2014.09.004. Epub 2014 Sep 27.
9. Máira Chiarelli Serra, Claudia Menicanti, Elisabetta Pennacchioli, Giulio Tosti. Vulvar vitiligo-like depigmentation and multiple halos of hypomelanosis at the trunk

- following treatment with imiquimod 5% cream for vulvar condylomata: casual or related events? *An Bras Dermatol.* 2014 Sep-Oct; 89(5): 806–807.
10. Sara Gandini, Esther De Vries, Giulio Tosti, Edoardo Botteri, Giuseppe Spadola, Patrick Maisonneuve, Chiara Martinoli, Arjen Joosse, Pier Francesco Ferrucci, Federica Baldini, Emilia Cocorocchio, Elisabetta Pennacchioli, Francesco Cataldo, Barbara Bazolli, Alessandra Clerici, Massimo Barberis, Veronique Bataille, Alessandro Testori. Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy. *PLoS One.* 2013; 8(11): e78820. Published online 2013 Nov 4.
 11. E Cocorocchio, S Gandini, S Alfieri, A Battaglia, E Pennacchioli, G Tosti, G Spadola, M Barberis, M Di Leo, C Riviello, L Pala, A Intelisano, C Martinoli, PF Ferrucci. Dabrafenib in metastatic melanoma: a monocentric 'real life' experience. *Ecancermedicalscience.* 2016; 10: 624. Published online 2016 Mar
 12. Tosti G, Cocorocchio E, Pennacchioli E, Ferrucci PF, Testori A, Martinoli C. Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. *Expert Opin Biol Ther.* 2014 Jul;14(7):955-67. Epub 2014 Mar 26.
 13. Serra MC, Menicanti C, Pennacchioli E, Tosti G. Vulvar vitiligo-like depigmentation and multiple halos of hypomelanosis at the trunk following treatment with imiquimod 5% cream for vulvar condylomata: casual or related events? *An Bras Dermatol.* 2014 Sep-Oct;89(5):806-7.
 14. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. *Eur J Cancer.* 2014 Nov;50(17):3021-8. Epub 2014 Sep 27.
 15. Vitali GC, Trifirò G, Zonta M, Pennacchioli E, Santoro L, Travaini LL, Barberis M, Testori A. Lymphoscintigraphy in clinical routine practice: Reproducibility and accuracy in melanoma patients with a long-term follow-up. *Eur J Surg Oncol.* 2014 Jan;40(1):55-60. Epub 2013 Sep 12

16. Tosti G, Cocorocchio E, Pennacchioli E. Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. *Clin Cosmet Investig Dermatol*. 2013 Oct 17;6:245-56. Review.
17. Gandini S, De Vries E, Tosti G, Botteri E, Spadola G, Maisonneuve P, Martinoli C, Joosse A, Ferrucci PF, Baldini F, Cocorocchio E, Pennacchioli E, Cataldo F, Bazolli B, Clerici A, Barberis M, Bataille V, Testori A. Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in Italy. *PLoS One*. 2013 Nov 4;8(11)
18. Mozzillo N, Pennacchioli E, Gandini S, Caracò C, Crispo A, Botti G, Lastoria S, Barberis M, Verrecchia F, Testori A. Sentinel Node Biopsy in Thin and Thick Melanoma. *Ann Surg Oncol*. 2013 May 30.
19. Mattavelli F, Pizzi N, Pennacchioli E, Radaelli S, Quattrone P, Mattavelli D, Fior A, Pilotti S. Neoplastic lymphangiosis of the upper aerodigestive tract simulating field cancerization: histopathological analysis, surgical limits and literature review. *Tumori*. 2012 Jul-Aug;98(4):e115-7.
20. Testori A, Intelisano A, Verrecchia F, Menicanti C, Tosti G, Grassi E, Pari C, Pennacchioli E. Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role? *Dermatol Ther*. 2012 Sep-Oct;25 (5): 443-51
21. Pennacchioli E, Tosti G, Barberis M, De Pas TM, Verrecchia F, Menicanti C, Testori A, Mazzarol G. Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread? *Clin Exp Metastasis*. 2012 Oct;29 (7): 757-73
22. Testori A, Thompson JF, Eggermont AMM, Faries M, Pennacchioli E, Kroon HM. Loco-regional Treatment of Melanoma Metastases in a Limb by Isolated Limb Perfusion and Isolated Limb Infusion. *J Surg Oncol*. 2011 Sep;104 (4): 397-404.
23. Testori A, Faries M, Thompson JF, Pennacchioli E, Deroose JP, Van Geel AN, Verhoef C, Verrecchia F, Soteldo J. Therapy of In-Transit Melanoma Metastases. *J Surg Oncol*. 2011 Sep;104 (4): 391-6

24. Berselli M, Coppola S, Colombo C, Pennacchioli E, Fiore M, Gronchi A. Morbidity of left pancreatectomy when associated with multivisceral resection for abdominal mesenchymal neoplasms. *JOP* 2011 Mar 9; 12 (2): 138-44.
25. Sanfilippo R, Miceli R, Grosso F, Fiore F, Puma E, Pennacchioli E, Barisella M, Sangalli C, Mariani L, Casali PG, Gronchi A. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Ann Surg Oncol* 2011 Mar; 18(3):720-5. Epub 2010 Sep 28.
26. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG, Gronchi A. Alveolar soft part sarcoma: clinical presentation, treatment and outcome in a series of 33 patient at a single Institution. *Ann Surg Oncol*, 2010 Dec; 17(12): 3229-33. Epub 2010 Jul 1.
27. Pennacchioli E, Colombo C, Berselli M, Gronchi A. Update on the management of GIST and post-surgical use of Imatinib. *Dove Medical Press*, in press.
28. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, Gronchi A, Deraco M. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? *Ann Surg Oncol* 2010 Dec; 17(12): 3220-8. Epub 2010 Jun 29.
29. Mattavelli F, Pizzi N, Pennacchioli E, Radaelli S, Calarco G, Quattrone P, Patelli L, Spinelli P. *Acta Otorhinolaryngol Ital* 2009 Jun; 29(3):164-8.
30. Mattavelli F, Collini P, Pizzi N, Nicolai N, Pennacchioli E. Thyroid Study Group. Thyroid as a target of metastases: a case of metastatic seminoma in a patient who died of a second cancer. *Tumori* 2009 Jan-Feb; 95(1):91-3.
31. Pennacchioli E, Fiore M and Gronchi A. Hyperthermia as a adjunctive treatment for soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2009 Feb, 9(2): 199-210.
32. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG and Gronchi A. Preoperative Imatinib mesylate for unresectable or locally advanced primary Gastrointestinal Stromal Tumors (GIST). *Eur J Surg Oncol* 2009 Jul;35(7):739-45. Epub 2008 Dec 24.

33. Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L and Casali PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol* 2009; 27(1): 24-30.
34. Mattavelli F, Collini P, Pizzi N, Gervasoni C, Pennacchioli E, Mazzaferro V. Thyroid as a target of metastases. A case of foregut neuroendocrine carcinoma with multiple abdominal metastases and a thyroid localization after 21 years. *Tumori* 2008 Jan-Feb;94(1):110-3
35. Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Redaelli S, Fiore M and Gronchi A. Epithelioid Sarcoma: Prognostic Factors and Survival in a series of Patients Treated at a Single Institution. *Ann Surg Oncol* 2007; 14(12):3542-51.
36. Mattavelli F, Bombardieri E, Collini P, Costa L, Pizzi N, Falladhar D, Pennacchioli E, Santamaria S, Cascinelli N. Role of surgery in treatment of advanced differentiated thyroid carcinoma. *Acta Otorhinolaryngol Ital* 2007 Apr; 27(2):62-7
37. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG and Gronchi A. Myxoid/round cell and pleomorphic liposarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 2007; 109: 2522-2531.
38. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M and Gronchi A. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. *Ann Surg Oncol* 2007; 14(2): 553-9.
39. Cascinelli N, Bombardieri E, Bufalino R, Camerini T, Carbone A, Clemente C, Lenisa L, Mascheroni L, Maurichi A, Pennacchioli E, Patuzzo R, Santinami M, Tragni G. Sentinel and non-sentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. *J Clin Oncol* 2006 Sep 20;24(27):4464-71
40. Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100

peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. *Cancer Res* 2006 May 1;66(9):4943-51

41. Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchianò A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Di Florio A, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. *Cancer Immunol Immunother* 2006 Aug;55(8):958-68. Epub 2005 Oct 8
42. Mortarini R, Scarito A, Nonaka D, Zanon M, Bersani I, Montaldi E, Pennacchioli E, Patuzzo R, Santinami M, Anichini A. Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles. *Cancer Res* 2005 Apr 15;65(8):3428-36
43. Ferrari A, Bono A, Baldi M, Collini P, Casanova M, Pennacchioli E, Terenziani M, Marcon I, Santinami M, Bartoli C. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. *Pediatrics* 2005 Mar;115(3):649-54
44. Maurichi A, Baldi M, Bartoli C, Bono A, Camerini T, Moglia D, Patuzzo R, Pennacchioli E, Tragni G, Santinami M. Pigmented spindle-cell nevus: a melanoma simulator. *Dermatol Online J* 2004 Oct 15;10(2):5
45. Santinami M, Baldi M, Tragni G, Maurichi A, Moglia D, Bono A, Bartoli C, Patuzzo R, Pennacchioli E, Cascinelli N. [Impact of sentinel lymph node biopsy on the treatment of melanoma]. *Tumori* 2003 Jul-Aug;89(4Suppl):273-5
46. Deraco M, Casali P, Inglese MG, Baratti D, Pennacchioli E, Bertulli R, Kusamura S. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery and intraperitoneal hyperthermic perfusion. *J Surg Oncol* 2003 Jul;83(3):147-53
47. Cascinelli N, Santinami M, Maurichi A, Patuzzo R, Pennacchioli E. World Health Organization experience in the treatment of melanoma. *Surg Clin North Am*. 2003 Apr;83(2):405-16. Review

48. Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M, Santinami M. Chordoma: natural history and results in 28 patients treated at a single institution. *Ann Surg Oncol*. 2003; 10(3):291-6.
49. Deraco M, Gronchi A, Mazzaferro V, Inglese MG, Pennacchioli E, Kusamura S, Rizzi M, Anselmi RA Jr, Vaglini M. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. *Tumori*. 2002, 88(5):370-5.
50. Santinami M, Maurichi A, Patuzzo R, Pennacchioli E, Cascinelli N. Impact of clinical trials on the treatment of melanoma. *Surg Oncol Clin N Am* 2001 Oct;10(4):935-47
51. Azzarelli A., Gronchi A., Bertulli R., Tesoro Tess J.D., Baratti D., Pennacchioli E., Dileo P., Rasponi A., Pilotti S., Casali P.G. Low-dose chemotherapy with Methotrexate and Vinblastine for advanced aggressive fibromatosis. *Cancer* 2001, 92 (5): 1259-1264.
52. Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, Raspagliesi F, Kusamura S, Vaglini M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. *Tumori* 2001 May-Jun;87(3):120-6
53. Di Palo S, Pennacchioli E, Ossi C, Di Carlo V. Microbiological analysis of post-operative infectious complications. *Minerva Chir* 1991 Apr 30;46(8):369-73

List of Book chapters 2018.pdf

List of Book chapters, in English

1. **Pennacchioli E**, Barberis M, Rizzo, S. Pattern and Management of Recurrent Retroperitoneal Liposarcoma. Updates in surgery. V. Quagliuolo, A. Gronchi (Eds), Current treatment of retroperitoneal sarcomas.
2. **Pennacchioli E**, Veronesi P. Surgery of metastases. Oncological surgery. Breast Cancer: Innovations in Research and Management. Chief editors: Umberto Veronesi and Aron Goldhirsch. July 12, 2017
3. Santinami M, Gronchi A, Maurichi M, Zoras O, Patuzzo R, **Pennacchioli E**. Limb's perfusion: rationale, techniques and results. In Zoras O ed: Regional Oncotherapies. Athens: Paschalidis Medical Publications Ltd; 2006:193-226.
4. Cascinelli N., Clemente C., Maurichi A., Patuzzo R., **Pennacchioli E.**, Rao S., Satinami M. I melanomi. Trattato di Chirurgia Oncologica. F. Mazzeo, P. Forestieri. Picci Editore, 2003.
5. Vaglini M., Deraco M., **Pennacchioli E**. Regional Chemotherapy for Solid Tumors. Surgical Oncology – Contemporary principles and practice. Kirb I. Bland, John M. Daly, Constantine P. Karakousis. Editore Mc Graw-Hill, 2001.